About Health Life Digest
Health Life Digest is an independent health journalism publication dedicated to providing accurate, evidence-based coverage of GLP-1 receptor agonist medications. Our editorial team produces in-depth reporting on treatment side effects, insurance coverage policies, and clinical outcomes.
Our Mission
The GLP-1 medication landscape is evolving rapidly. Millions of patients are navigating complex insurance policies, managing side effects, and making treatment decisions with limited access to reliable information. Health Life Digest exists to fill that gap with rigorous, accessible journalism.
Editorial Standards
Every article published by Health Life Digest undergoes a multi-step review process:
- Research is drawn from peer-reviewed clinical trials, FDA documentation, and official prescribing information
- Insurance coverage information is verified against current formulary databases and plan documentation
- Medical claims are reviewed for accuracy against established clinical guidelines
- Content is updated regularly to reflect policy changes and new research findings
Medications We Cover
Our coverage focuses on the four leading GLP-1 receptor agonist medications prescribed for diabetes management and weight loss:
- Ozempic (semaglutide) — Manufactured by Novo Nordisk, approved for type 2 diabetes
- Wegovy (semaglutide, higher dose) — Manufactured by Novo Nordisk, approved for chronic weight management
- Mounjaro (tirzepatide) — Manufactured by Eli Lilly, approved for type 2 diabetes
- Zepbound (tirzepatide) — Manufactured by Eli Lilly, approved for chronic weight management
Insurance Coverage Reporting
Our insurance coverage guides analyze policies from major U.S. health insurance providers including Medicare, Medicaid, Aetna, Anthem Blue Cross, Cigna, Express Scripts, Humana, Kaiser Permanente, TRICARE, and UnitedHealthcare. Each guide details formulary status, prior authorization requirements, step therapy protocols, and appeal strategies.
Contact
For editorial inquiries, corrections, or feedback, contact our team at editorial@healthlifedigest.com.